Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Small Cell Lung Carcinoma 1Lymphoma 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Congenital Abnormalities 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 16Peripheral Blood Stem Cell Transplantation 14Cytarabine 12Cyclophosphamide 12Whole-Body Irradiation 10Filgrastim 9Cyclosporine 9Busulfan 9Mycophenolic Acid 8Tacrolimus 7Etoposide 7Antilymphocyte Serum 7Radiotherapy 6Methotrexate 6Granulocyte Colony-Stimulating Factor 6Cord Blood Stem Cell Transplantation 6Methylprednisolone 5Flow Cytometry 5Thiotepa 4Mitoxantrone 4Melphalan 4Idarubicin 4Decitabine 4fludarabine 3aldesleukin 3Transplantation 3Interleukin-2 3Bortezomib 3Alemtuzumab 3Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Congenital Abnormalities × Podophyllotoxin × Clear all
NCT00540995 2023-11-30

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

City of Hope Medical Center

Phase 1/2 Terminated
25 enrolled 9 charts
Classical hematologyOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡